Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Targeting Oncogenic Enhancers in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Terra L Lasho, Christy M Finke, Jenna A. Fernandez, Christopher T. Schmitz, Karl J. Clark, Claes Wahlestedt, Judy Chiao, Abhishek A Mangaonkar, Mrinal M. Patnaik, Moritz Binder

Blood (2023) 142 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2023-178083

Published: 2023

Journal Articles

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Blood (2017) 130 (Supplement 1): 891.

https://doi.org/10.1182/blood.V130.Suppl_1.891.891

Published: 2017

Journal Articles

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Guillermo Garcia-Manero, MD, Selina M Luger, MD, Stuart Goldberg, MD, Jessica K Altman, MD, Martha Arellano, MD, Meir Wetzler, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M Kantarjian, MD

Blood (2013) 122 (21): 2752.

https://doi.org/10.1182/blood.V122.21.2752.2752

Published: 2013

Journal Articles

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Farhad Ravandi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, PhD, Stuart L. Goldberg, MD, Meir Wetzler, MD, Parameswaran Venugopal, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2630.

https://doi.org/10.1182/blood.V120.21.2630.2630

Published: 2012

Journal Articles

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,

Farhad Ravandi, MD, Stefan Faderl, MD, Jorge E. Cortes, Guillermo Garcia-Manero, Elias Jabbour, Patricia Ann Boone, Tapan Kadia, Gautam Borthakur, William G. Wierda, MD, PhD, Meir Wetzler, MD, Parameswaran Venugopal, MD, Judy Chiao, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3630.

https://doi.org/10.1182/blood.V118.21.3630.3630

Published: 2011

Journal Articles

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents

Guillermo Garcia-Manero, MD, Selina Luger, MD, Parmeswaran Venugopal, MD, Lori Maness, MD, Meir Wetzler, MD, Jessica K Altman, MD, David F. Claxton, MD, Stephen Anthony Strickland, JR, MD, James M. Foran, MD, FRCPC, Stuart L Goldberg, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 1857.

https://doi.org/10.1182/blood.V116.21.1857.1857

Published: 2010

Journal Articles

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.

Guillermo Garcia-Manero, MD, Selina Luger, MD, Parameswaran Venugopal, MD, Lori J. Maness, MD, Meir Wetzler, MD, Jessica Altman, MD, David F. Claxton, M.D., Stephen Strickland, MD, Stefan Faderl, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 1758.

https://doi.org/10.1182/blood.V114.22.1758.1758

Published: 2009

Journal Articles

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse.

Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Selina Luger, MD, Parameswaran Venugopal, MD, Lori J. Maness, MD, Meir Wetzler, MD, Wendy Stock, MD, Steven Coutre, MD, Gautam Borthakur, MD, Judy Chiao, MD

Blood (2009) 114 (22): 1061.

https://doi.org/10.1182/blood.V114.22.1061.1061

Published: 2009

Journal Articles

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Paul G. Richardson, Constantine S. Mitsiades, Kathleen Colson, Eileen Reilly, Laura McBride, Judy Chiao, Linda Sun, Justin L. Ricker, Syed Rizvi, Carol Oerth, Barbara Atkins, Ivy Fearen, Kenneth C. Anderson, David S. Siegel

Blood (2007) 110 (11): 1179.

https://doi.org/10.1182/blood.V110.11.1179.1179

Published: 2007

NARROW

Targeting Oncogenic Enhancers in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse.

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only